Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 685-694

  Kurosaki, Masayuki ^a   Tanaka, Yasuhito ^b   Tanaka, Keisuke ^a   Suzuki, Yuichiro ^a,c   Hoshioka, Yoshihide ^a   Tamaki, Nobuharu ^a   Kato, Tomoji ^a   Yasui, Yutaka ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Kuzuya, Teiji ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Takahashi, Yuka ^a   Asahina, Yasuhiro ^a   Matsuura, Kentaro ^b   Sugauchi, Fuminaka ^b   Enomoto, Nobuyuki ^c   Nishida, Nao ^d   Tokunaga, Katsushi ^d   Mizokami, Masashi ^e   Izumi, Namiki ^a   more..

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e Japan Konodai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IL2B GENE; ITPA GENE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79960732391     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1796     Document Type: Article

References (27)

1. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
3. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
4. Fellay J., Thompson A.J., Ge D., et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-408.
5. Sumi S., Marinaki A.M., Arenas M., et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111:360-367. (Pubitemid 36075062)
6. Maeda T., Sumi S., Ueta A., et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005; 85:271-279. (Pubitemid 41074110)
7. Shipkova M., Lorenz K., Oellerich M., Wieland E., Von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006; 52:240-247 (Pubitemid 43185485)
8. Atanasova S., Shipkova M., Svinarov D., et al. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit 2007; 29:6-10. (Pubitemid 46279870)
9. Thompson A.J., Fellay J., Patel K., et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139:1181-1189.
10. Ochi H., Maekawa T., Abe H., et al. Inosine triphosphate pyrophosphatase polymorphism affects ribavirin- Induced anemia and outcomes of therapy - a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology 2010; 139:1190-1197.
11. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
12. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
13. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
14. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010; 138:1338-1345.
15. Nishida N., Tanabe T., Takasu M., Suyama A., Tokunaga K. Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem 2007; 364:78-85. (Pubitemid 46497954)
16. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-82.
17. Kurosaki M., Enomoto N., Murakami T., et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25:750-753. (Pubitemid 27106465)
18. Akuta N., Suzuki F., Sezaki H., et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48:372-380. (Pubitemid 41003622)
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293. (Pubitemid 26260021)
21. Tanaka Y., Nishida N., Sugiyama M., Tokunaga K., Mizokami M. λ-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 2010; 40:449-460.
22. Bronowicki J.P., Ouzan D., Asselah T., et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048. (Pubitemid 44515099)
23. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
24. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
25. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
26. Hiramatsu N., Oze T., Tsuda N., et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006; 35:185-189.
27. Iwasaki Y., Ikeda H., Araki Y., et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54-63. (Pubitemid 43733592)